Abstract
Purpose
Two human papillomavirus (HPV) vaccines are available to prevent cervical cancer. One early measure of HPV vaccine impact would be a reduction in vaccine-related HPV types (HPV 6, 11, 16, or 18, or HPV 16, 18) in cervical samples from young women. We aimed to assess feasibility of specimen collection and baseline HPV prevalence in an integrated healthcare delivery system.
Methods
Residual cervical specimens collected during routine cervical cancer screening (2006–2008) were retained consecutively from eligible females aged 11–29 years, stratified by age group. Specimens were evaluated for 37 HPV genotypes using the Roche Linear Array assay.
Results
Of 10,124 specimens submitted, 10,103 (99 %) were adequate for HPV testing. Prevalence of HPV 6, 11, 16, or 18 genotype was 11.4 % overall and was the highest in the youngest age group (18.1 % in the 11–19-year-olds, 12.5 % in the 20–24-year-olds, and 7.0 % in the 25–29-year-olds).
Conclusions
HPV types 6, 11, 16, or 18 prevalence could be measured over time to assess early HPV vaccine impact using residual specimens from an integrated healthcare delivery system, particularly if sampling focused on young women.
This is a preview of subscription content, log in via an institution to check access.
References
CDC (2010) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 59(20):626–629
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007) Quadrivalent human papillomavirus vaccine, recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 56(RR02):1–24
Dunne EF, Datta SD, Markowitz LE (2008) A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Vaccine 113(10):2995–3004
Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 297:813–819
Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE (2011) Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. J Infect Dis 204(4):566–573
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324:17–27
Munoz N, Bosch FX, de Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527
Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, Patel S, Unger ER (2011) Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National Health and Nutrition Examination Survey, 2003–2006: opportunity to measure HPV vaccine impact? J Infect Dis 204(4):562–565
Manhart LE, Holmes KK, Koutsky LA et al (2006) Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 33:502–508
Shikary T, Bernstein DI, Jin Y, Zimet GD, Rosenthal SL, Kahn JA (2009) Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. J Clin Virol 46:107–111
Gaffga NH, Flagg EW, Weinstock HS, Shlay JC, Ghanem KG, Koutsky LA, Kerndt PR, Hsu KK, Unger ER, Datta SD (2012) Monitoring HPV type-specific prevalence over time through clinic-based surveillance: a perspective on vaccine effectiveness. Vaccine 30(11):1959–1964
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD1, Robertson M, Shearman CA, Castle PE for The New Mexico HPV Pap Registry Steering Committee (2013) A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 132:198–207
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D et al., HPV PATRICIA Study Group, Greenacre M (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301–314
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–1943
The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–1927
Saslow D et al (2002) American cancer society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52:342–362
Acknowledgments
The authors would like to acknowledge the important contributions of Charlie Chao and Kristine Bennett for assistance with identifying and shipping specimens, and Jim Braxton and Suzanne Powell for assistance with the database and analysis. This study was funded by CDC through America’s Health Insurance Plans (AHIP) contract number: 200-2002-00732.
Conflicts of interest
All CDC authors and K Reidlinger have no conflicts of interest. R Baxter and NP Klein have received research grants from Merck and GSK. A Naleway and S Weinmann have received research grants from GSK.
Author information
Authors and Affiliations
Corresponding author
Additional information
CDC Disclaimer The findings and conclusions in this article are those of the authors and do not necessarily represent the views of CDC.
Rights and permissions
About this article
Cite this article
Dunne, E.F., Klein, N.P., Naleway, A.L. et al. Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control 24, 403–407 (2013). https://doi.org/10.1007/s10552-012-0085-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-012-0085-9